EPIC is a Twin Cities-based investment club based the proven NAIC principles of investing regularly, reinvesting earnings, investing in growth companies, and diversifying to reduce risk. Our Mission Statement is to double our investment every 5 years, achieving a 15% compounding annual return.
$EXAS – Q3 Earnings / Stock Update

$EXAS – Q3 Earnings / Stock Update

Posted by on Nov 3, 2011 in Stock Updates | 0 comments |

Exact Sciences reported a .15 loss during Q3, inline with analyst estimates.  Revenue was slightly below estimates coming in at $1MM vs  the $1.03MM esimate.

The company stated the clinical trial of Cologuard continues to progress on track and that, obviously, the completion of the trial remains the company’s top priority.

This continues to fall in the “No news is good news” we were looking for.  As stated before, the clinical trial is expected to take some time and any news released regarding the trial will more than likely be informing us of a delay or added expense to the company.  The Biotech industry has a huge conference in June of this year and if the company stays on track with the trial the stock should really gain some ground as the conference grows closer.

Since the last meeting, this stock is up approximately 4.75%.

My sentiment is to continue to hold this position.



Leave a Reply